Media

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

[email protected]

Sort by Year

May 17, 2021

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

May 6, 2021

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

May 6, 2021

Ironwood Pharmaceuticals Reports First Quarter 2021 Results

April 22, 2021

Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call

February 19, 2021

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

February 17, 2021

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance

February 8, 2021

Ironwood Pharmaceuticals Announces CEO Transition

February 3, 2021

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call

January 5, 2021

Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 3, 2020

Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors

November 6, 2020

Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference

November 5, 2020

Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance

November 5, 2020

Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors

October 22, 2020

Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call

September 29, 2020

Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment